An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium.

This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with .sup.64Cu or .sup.18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.

This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with .sup.64Cu or .sup.18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.

A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10 % by weight to 20 % by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose.

A nanoparticle composition is provided. The nanoparticle composition includes a plurality of nanoparticles, each nanoparticle of the plurality having a core including tantalum oxide, and a covalent coating covalently bound to the core. The covalent coating includes a surface modifier selected from the group consisting of (3-aminopropyl)trimethoxy silane (APTMS), (3-aminopropyl)triethoxy silane (APTES), APTMS-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTMS-m-PEG-glutarate), APTES-methoxy-poly(ethylene-glycol)-succinimidyl glutarate (APTES-m-PEG-glutarate), 2-[methoxy (polyethyleneoxy)-9-12-propyl] trimethoxysilane (PEG-Silane), hexadecyltriethoxy silane, and combinations thereof. Methods of synthesizing and using the nanoparticle composition are also provided.

A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed.

A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed.

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.